XML 79 R68.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 9,930 | $ 9,844 | $ 19,365 | $ 19,156
Proceeds from sale of marketing rights |  |  | 50 | 75
corticotropin marketing rights |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Proceeds from sale of marketing rights |  |  |  | 75
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 9,815 | 9,680 | 19,033 | 18,689
Operating Segments | Total Pharmaceutical segment sales |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,759 | 8,700 | 16,944 | 16,804
Operating Segments | Total Pharmaceutical segment sales | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 367 | 702 | 701 | 1,314
Operating Segments | Total Pharmaceutical segment sales | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 182 | 293 | 423 | 570
Operating Segments | Total Pharmaceutical segment sales | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 33 | 112 | 56
Operating Segments | Total Pharmaceutical segment sales | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 40 | 151 | 72
Operating Segments | Total Pharmaceutical segment sales | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 948 | 1,064 | 1,787 | 1,970
Operating Segments | Total Pharmaceutical segment sales | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 563 | 569 | 1,059 | 1,075
Operating Segments | Total Pharmaceutical segment sales | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 199 | 200 | 359 | 376
Operating Segments | Total Pharmaceutical segment sales | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 178 | 164 | 349 | 298
Operating Segments | Total Pharmaceutical segment sales | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 79 | 73 | 160 | 167
Operating Segments | Total Pharmaceutical segment sales | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 517 | 112 | 895 | 161
Operating Segments | Total Pharmaceutical segment sales | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 282 | 338 | 587 | 678
Operating Segments | Total Pharmaceutical segment sales | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 163 | 113 | 310 | 204
Operating Segments | Total Pharmaceutical segment sales | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 155 | 143 | 296 | 288
Operating Segments | Total Pharmaceutical segment sales | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 150 | 143 | 286 | 257
Operating Segments | Total Pharmaceutical segment sales | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 112 | 131 | 233 | 263
Operating Segments | Total Pharmaceutical segment sales | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 357 | 198 | 649
Operating Segments | Total Pharmaceutical segment sales | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 81 | 133 | 154
Operating Segments | Total Pharmaceutical segment sales | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 208 | 339 | 437 | 688
Operating Segments | Total Pharmaceutical segment sales | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 199 | 199 | 383 | 387
Operating Segments | Total Pharmaceutical segment sales | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 881 | 314 | 1,465 | 563
Operating Segments | Total Pharmaceutical segment sales | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 143 | 143 | 276 | 268
Operating Segments | Total Pharmaceutical segment sales | Temodar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 73 | 130 | 139
Operating Segments | Total Pharmaceutical segment sales | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 203 | 229 | 389 | 465
Operating Segments | Total Pharmaceutical segment sales | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 85 | 101 | 224 | 331
Operating Segments | Total Pharmaceutical segment sales | Dulera |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 69 | 121 | 151 | 234
Operating Segments | Total Pharmaceutical segment sales | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 119 | 132 | 231 | 258
Operating Segments | Total Pharmaceutical segment sales | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 89 | 117 | 192 | 228
Operating Segments | Total Pharmaceutical segment sales | Fosamax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 66 | 73 | 127 | 148
Operating Segments | Total Pharmaceutical segment sales | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 469 | 393 | 1,001 | 770
Operating Segments | Total Pharmaceutical segment sales | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 399 | 383 | 754 | 739
Operating Segments | Total Pharmaceutical segment sales | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 123 | 130 | 347 | 318
Operating Segments | Total Pharmaceutical segment sales | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 166 | 120 | 329 | 228
Operating Segments | Total Pharmaceutical segment sales | Zostavax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 160 | 149 | 313 | 274
Operating Segments | Total Pharmaceutical segment sales | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,116 | 1,128 | 2,156 | 2,214
Operating Segments | Other segment sales |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,056 | 980 | 2,089 | 1,885
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 115 | $ 164 | $ 332 | $ 467

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mrk_CorticotropinmarketingrightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_TemodarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_DuleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_FosamaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_GardasilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_ZostavaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |